Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers

被引:19
作者
Zelek, Wioleta M. [1 ,2 ]
Harris, Claire L. [3 ]
Morgan, B. Paul [1 ,2 ]
机构
[1] Cardiff Univ, Syst Immun Res Inst, Sch Med, Cardiff CF14 4XN, S Glam, Wales
[2] Cardiff Univ, Div Infect & Immun, Sch Med, Cardiff CF14 4XN, S Glam, Wales
[3] Newcastle Univ, Med Sch, Inst Cellular Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
Complement; Haemolysis assay; Complement fixation test; Buffer;
D O I
10.1016/j.imbio.2018.07.016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Complement assays have for many years utilised buffers based on barbitone (veronal) despite the well-re-cognised toxicity of this agent and the tight regulations on its use in most countries. The use of barbitone in complement assay buffers is steeped in history, from a time when no other suitable buffers were available. This is no longer the case, encouraging us to explore alternatives to barbitone for complement assays. We compared a simple, non-toxic HEPES buffer with commercially sourced complement fixation test diluent (CFD), the "gold standard" barbitone buffer, in several clinically relevant complement activity assays and across species. In classical pathway haemolysis assays in human and non-human serum, there was no difference in haemolytic curves or calculated haemolytic activity (CH50) between CFD and an optimised HEPES buffer (HBS) supplemented with cations. Alternative pathway haemolysis assays in human serum were also identical in the two buffers. In a complement fixation test for anti-erythrocyte antibodies, complement consumption was identical for the two buffer systems. The data demonstrate that barbitone-based buffers are unnecessary for assays of complement activity and can readily be replaced with safe and simple alternatives.
引用
收藏
页码:744 / 749
页数:6
相关论文
共 25 条
[1]   Resolving Transferrin lsoforms via Agarose Gel Electrophoresis [J].
Anani, Waseem Q. ;
Ojerholm, Eric ;
Shurin, Michael R. .
LABMEDICINE, 2015, 46 (01) :26-33
[2]  
[Anonymous], 1997, NON TRADITIONAL REF, V74, DOI [10.2307/2664489.http://www.jstor.org/openurl?sid=primo&volume=74&date=1999&spage=1168,issn=00335770&issue=1, DOI 10.2307/2664489]
[3]  
Barnum SR., 2018, The Complement Factsbook, V2nd
[4]  
BATEMAN CH, 1963, LANCET, V2, P357
[5]   An international serum standard for application in assays to detect human complement activation products [J].
Bergseth, Grethe ;
Ludviksen, Judith K. ;
Kirschfink, Michael ;
Giclas, Patricia C. ;
Nilsson, Bo ;
Mollnes, Tom E. .
MOLECULAR IMMUNOLOGY, 2013, 56 (03) :232-239
[6]  
Breadstreet CM, 1962, MON B MINIST HLTH PU, V21, P96
[7]   Mechanism of hemolysis by complement. I. Complement fixation as an essential preliminary to hemolysis. [J].
Eagle, H ;
Brewer, G .
JOURNAL OF GENERAL PHYSIOLOGY, 1929, 12 (06) :845-862
[8]   Advances in assay of complement function and activation [J].
Harboe, Morten ;
Thorgersen, Ebbe Billmann ;
Mollnes, Tom Eirik .
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (12) :976-987
[9]   Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay [J].
Harris, Claire L. ;
Pettigrew, David M. ;
Lea, Susan M. ;
Morgan, B. Paul .
JOURNAL OF IMMUNOLOGY, 2007, 178 (01) :352-359
[10]   Quantitative chemical studies on complement or alexin II. The interrelation of complement with antigen-antibody compounds and with sensitized red cells [J].
Heidelberger, M ;
Weil, AJ ;
Treffers, HP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1941, 73 (06) :695-709